Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy

被引：0
作者：
Praveen K. Bommareddy
Megha Shettigar
Howard L. Kaufman
机构：
[1] Rutgers Graduate School of Biomedical Sciences,
[2] Dana- Farber Cancer Institute,undefined
[3] Replimune,undefined
[4] Inc,undefined
[5] Massachusetts General Hospital,undefined
来源：
Nature Reviews Immunology | 2018年 / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In the initially published version of this article online in advance of print, a reference (Ajina, A. & Maher, J. Prospects for combined use of oncolytic viruses and CAR T-cells. J. Immunother. Cancer 5, 90 (2017)) was omitted in error from the following sentence: “The ability of oncolytic viruses to increase the expression of MHC class I molecules by cancer cells is also predicted to enhance ACT with TILs or TCR-engineered and chimeric antigen receptor (CAR) T cells that target tumour-specific antigens”. This has been corrected in the HTML and PDF versions of the manuscript.
引用
收藏
页码：536 / 536
相关论文
共 50 条
[41]   Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer [J].
Guo, Zong Sheng ;
Bartlett, David L. .
BIOMEDICINES, 2017, 5 (03)
[42]   Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment [J].
Zhang, Ling ;
Pakmehr, Seyed Abbas ;
Shahhosseini, Reza ;
Hariri, Maryam ;
Fakhrioliaei, Azadeh ;
Shayan, Farid Karkon ;
Xiang, Wenxue ;
Shayan, Sepideh Karkon .
MEDICAL ONCOLOGY, 2023, 41 (01)
[43]   Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors [J].
Park, Anthony K. ;
Fong, Yuman ;
Kim, Sang-In ;
Yang, Jason ;
Murad, John P. ;
Lu, Jianming ;
Jeang, Brook ;
Chang, Wen-Chung ;
Chen, Nanhai G. ;
Thomas, Sandra H. ;
Forman, Stephen J. ;
Priceman, Saul J. .
SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (559)
[44]   Oncolytic viruses as engineering platforms for combination immunotherapy (vol 18, pg 419, 2018) [J].
Twumasi-Boateng, Kwame ;
Pettigrew, Jessica L. ;
Kwok, Y. Y. Eunice ;
Bell, John C. ;
Nelson, Brad H. .
NATURE REVIEWS CANCER, 2018, 18 (08) :526-526
[45]   Author Correction: Targeting public neoantigens for cancer immunotherapy [J].
Alexander H. Pearlman ;
Michael S. Hwang ;
Maximilian F. Konig ;
Emily Han-Chung Hsiue ;
Jacqueline Douglass ;
Sarah R. DiNapoli ;
Brian J. Mog ;
Chetan Bettegowda ;
Drew M. Pardoll ;
Sandra B. Gabelli ;
Nicholas Papadopoulos ;
Kenneth W. Kinzler ;
Bert Vogelstein ;
Shibin Zhou .
Nature Cancer, 2021, 2 :865-867
[46]   Oncolytic viruses as immunotherapy: progress and remaining challenges [J].
Aurelian, Laure .
ONCOTARGETS AND THERAPY, 2016, 9 :2627-2637
[47]   Oncolytic viruses: a new class of immunotherapy drugs [J].
Howard L. Kaufman ;
Frederick J. Kohlhapp ;
Andrew Zloza .
Nature Reviews Drug Discovery, 2015, 14 :642-662
[48]   Oncolytic viruses: a new class of immunotherapy drugs [J].
Kaufman, Howard L. ;
Kohlhapp, Frederick J. ;
Zloza, Andrew .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) :642-+
[49]   Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide [J].
Melcher, Alan ;
Parato, Kelley ;
Rooney, Cliona M. ;
Bell, John C. .
MOLECULAR THERAPY, 2011, 19 (06) :1008-1016
[50]   Oncolytic Viruses and Their Application to Cancer Immunotherapy (vol 2, pg 295, 2014) [J].
Chiocca, E. A. ;
Rabkin, S. D. .
CANCER IMMUNOLOGY RESEARCH, 2014, 2 (07) :699-699
12345